New Hampshire Clinical Trials Report — July 2026

New Hampshire residents considering a clinical trial should act promptly if they match a study nearing enrollment closure: 16 recruiting trials are expected to close within the next 90 days, including 6 that accept healthy volunteers. The most urgent opportunities involve breast cancer, atopic dermatitis, cognition, bleeding disorders, hearing loss, chronic kidney disease, atrial fibrillation, lung cancer, and fracture infection.

The state has 318 recruiting trials across 18 cities and 106 research sites. Five new studies opened in July, more than twice the 2 reported in May. That increase follows 2 new trials in June, although July remains below the February peak of 9.

Closing-soon studies create a narrow window

People with cancer make up the largest group among trials approaching closure. Three closing studies concern breast cancer, with another focused specifically on early-stage breast cancer. Other time-sensitive conditions include atopic dermatitis, cognition, bleeding, hearing loss, stage 4 chronic kidney disease, atrial fibrillation, extensive-stage small cell lung cancer, and fracture infection.

• Breast cancer — 3 closing-soon trials
• Atopic dermatitis, cognition, bleeding, hearing loss, chronic kidney disease stage 4, atrial fibrillation, early-stage breast cancer, extensive-stage small cell lung cancer, and fracture infection — 1 each

Healthy volunteers have opportunities as well: 6 of the 16 trials closing within 90 days accept people without the condition under study. Because screening, medical records review, and other enrollment steps can take time, prospective participants should contact study teams now rather than waiting until the stated closing period.

July brings a major Phase 3 lung cancer study

The most prominent new drug trial is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study, NCT07680790. It plans to enroll 850 participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. The study compares izalontamab brengitecan, also called BMS-986507, combined with osimertinib against osimertinib alone or osimertinib combined with platinum-based chemotherapy.

This is the only industry-sponsored trial among the 5 new July studies. The other new studies are classified as academic or otherwise sponsored, led by Dartmouth-Hitchcock Medical Center, Colby-Sawyer College, and Trustees of Dartmouth College. The month’s interventions include 2 behavioral studies, 1 drug study, 1 device study, and 1 study classified as other.

• NCT07680790 — Bristol-Myers Squibb’s Phase 3 comparison of izalontamab brengitecan plus osimertinib with established osimertinib-based treatments for EGFR-mutant non-small cell lung cancer.
• NCT07735715 — Dartmouth-Hitchcock Medical Center’s HOBSCOTCH-YOUTH and Young Adults study, planning to enroll 300 people ages 18 to 29 with epilepsy. It evaluates a home-based self-management program designed to improve thinking, memory, and quality of life.

The new-trial conditions are diverse. Researchers opened studies involving brain activity, breast cancer, cardiorespiratory fitness, cognitive benefits, cognitive dysfunction or cognitive disorder, epilepsy, healthy aging, memory and thinking problems, non-small cell lung cancer, and spine surgery. Several of these topics may appeal to older adults or people concerned about memory and independent functioning, while the epilepsy study specifically targets young adults.

Lebanon is the main July research hub

New trial activity is concentrated in Lebanon. Four of the 5 studies opened in July are listed there, while New London has 1 new study. This gives Lebanon a particularly strong position for people seeking recently opened research opportunities, especially those interested in the Dartmouth-Hitchcock and Dartmouth-affiliated programs.

• Lebanon — 4 new trials
• New London — 1 new trial

The broader recruiting network reaches 18 New Hampshire cities and 106 research sites, so current opportunities are not limited to the two cities with July openings. Still, the concentration of new studies in Lebanon suggests that residents near Dartmouth’s medical and academic facilities may have the greatest access to fresh enrollment slots. People elsewhere in the state should search by condition and ask whether a site is accepting local participants or requires travel.

Healthy volunteers and families have limited but meaningful options

Only 1 of the 5 new July trials accepts healthy volunteers, but 26 healthy-volunteer studies are recruiting statewide overall. The new healthy-volunteer opportunity appears among research on brain activity, fitness, cognition, healthy aging, or related topics rather than the July Phase 3 cancer trial.

Families should also review eligibility carefully. One new study includes children, and none of the new trials are restricted exclusively to women or men. Older adults are specifically included in 4 of the new studies, matching the month’s focus on healthy aging, memory and thinking, cognitive benefits, and related brain research.

People with breast cancer, lung cancer, kidney disease, atrial fibrillation, hearing loss, atopic dermatitis, or other conditions listed among the closing trials should make enrollment inquiries first. Healthy adults should review the 26 statewide options, while young adults with epilepsy may want to investigate NCT07735715. Eligibility can depend on disease stage, prior treatment, age, medications, test results, and travel availability.

New Hampshire’s research pipeline is likely to keep shifting as July’s Lebanon-heavy openings move into screening and the closing-soon studies reach their enrollment deadlines. Checking listings regularly and contacting research sites early will give patients, caregivers, and healthy volunteers the best chance to find an appropriate opportunity during the rest of summer 2026.